Literature DB >> 15721411

Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells.

Rong Zhou1, Oliver Treeck, Felicitas Horn, Olaf Ortmann.   

Abstract

OBJECTIVE: Tamoxifen, which is widely used in the treatment of breast cancer, also has a beneficial effect on cisplatin-refractory ovarian cancer. In this study, we investigated the long-term effects of this drug on estrogen-receptor-positive ovarian cancer cells.
METHODS: We performed an in vitro selection process by long-term treatment of BG-1 ovarian cancer cells with 4-hydroxy tamoxifen (4-OH TAM). Drug effects on cell growth were determined by measurement of relative cell numbers (MTS assay), the apoptotic effects of 4-OH TAM were determined by analysis of poly (ADP-ribose) polymerase (PARP) cleavage and by ELISA measurement of DNA-histone complexes in cytoplasm.
RESULTS: Analysis of BG-1(LT) ovarian cancer cells isolated after 5 months of long-term treatment with 4-OH TAM revealed both a significantly reduced apoptotic and antiproliferative effect of this drug. Further experiments to examine expression changes of the receptor tyrosine kinases EGFR, HER2 and estrogen receptor alpha did not reveal any alterations in BG-1(LT) if compared to wild-type cells. In contrast, in this cell line, a significant alteration in the expression of estrogen receptor beta was observed.
CONCLUSION: Our findings indicate that long-term treatment with 4-OH TAM is able to diminish both the antiproliferative and apoptotic action of this drug on BG-1 ovarian cancer cells. Our data suggest that the responsiveness of ovarian cancer cells to 4-OH TAM decreases after long-term treatment with this drug in vitro like previously observed after long-term treatment of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721411     DOI: 10.1016/j.ygyno.2004.11.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer.

Authors:  Hakan Karagol; Pinar Saip; Kazim Uygun; Murat Caloglu; Yesim Eralp; Faruk Tas; Adnan Aydiner; Erkan Topuz
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  The role of hormonal factors and endocrine therapy in ovarian cancer.

Authors:  Krystyna Serkies; Marcin Sinacki; Jacek Jassem
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15

3.  HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation.

Authors:  Elizabeth Lokich; Rakesh K Singh; Alex Han; Nicole Romano; Naohiro Yano; Kyukwang Kim; Richard G Moore
Journal:  Sci Rep       Date:  2014-06-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.